The Drug Development Process: Stages, Phases, and Timeline Explained

Bringing a new drug to market is one of the most complex and consequential undertakings in science. The drug development process typically spans 10 to 15 years, requires over $2.6 billion in investment, and involves thousands of researchers, regulators, and clinical trial participants before a single treatment reaches patients.

And the odds are not in favour of success. Only about 10–12% of drug candidates that enter clinical trials ultimately receive regulatory approval. The rest fail at some point along the way, often after years of research and hundreds of millions in sunk costs.

Every stage of drug development, from initial discovery in the laboratory to post-market safety surveillance, is designed to answer one fundamental question:

Is this drug safe and effective enough for human use?

In this guide, we’ll walk through each stage of the drug development process step by step, including timelines, phase success rates, and the regulatory checkpoints that every new medicine must clear.

Drug Discovery vs. Drug Development: What’s the Difference?

These terms are often used interchangeably, but they refer to distinct phases.

Drug discovery is the early-stage process of identifying and validating a biological target, screening chemical compounds, and selecting a lead candidate worth pursuing. It’s largely laboratory-based and exploratory.

Drug development is everything that follows the preclinical testing, clinical trials, regulatory submissions, and manufacturing validation required to bring that candidate to market.

In practice, the two phases overlap and feed into each other, which is why the full journey is often referred to as the drug discovery and development process.

5 Key Stages of Drug Development

1. Drug Discovery and Target Identification

The drug development journey begins in research laboratories, where scientists work to understand the biological mechanisms driving a specific disease. This involves identifying molecular targets (proteins, enzymes, receptors, or genetic sequences that play a role in the condition and could potentially be influenced by a therapeutic compound).

This stage covers three core activities:

Target identification and validation

Scientists analyze disease pathways to find a target — a specific molecule whose activity, if modified, could produce a therapeutic effect. Once identified, the target is validated through experiments to confirm it actually plays a meaningful role in the disease process.

High-throughput compound screening

Once a validated target exists, researchers screen large libraries of chemical compounds — sometimes hundreds of thousands — to find candidates that interact with it. This is essentially a large-scale search for a molecular “key” that fits a specific biological “lock.”

Lead optimization

Promising candidates go through rounds of structural refinement to improve their potency, selectivity, and drug-like properties. The goal is to identify a lead compound, one with strong enough activity and acceptable enough characteristics to advance into formal development.

This stage typically takes 3 to 6 years and does not involve human subjects.

2. Preclinical Research

Before any drug candidate is tested in humans, it must undergo rigorous preclinical evaluation. This stage assesses the compound’s safety profile, pharmacological activity, and biological behavior using in vitro (cell-based) and in vivo (animal) models.

The primary objectives of preclinical research are:

• Toxicology assessment: Researchers administer the compound across a range of doses from minimal to the highest tolerated to identify its toxicity threshold. Compounds with favorable safety profiles at higher doses are considered viable for advancement.
• Pharmacokinetic studies: These evaluate how the drug is absorbed, distributed, metabolized, and excreted (ADME) within a biological system—critical information for designing appropriate dosing regimens in human trials.
• Pharmacodynamic studies: These examine the drug’s biological effects at various dose levels, including its mechanism of action and duration of activity.

Preclinical studies use both rodent and non-rodent species to provide a comprehensive picture of safety before human exposure. Compounds that demonstrate acceptable toxicity and meaningful pharmacological activity proceed to the next step: the Investigational New Drug (IND) application.

IND Submission

Before clinical trials can begin in the U.S., the sponsor must file an Investigational New Drug (IND) application with the FDA. The IND includes all preclinical data, proposed clinical trial protocols, and manufacturing information. The FDA has 30 days to review the application and raise any concerns before trials may proceed.

Preclinical research typically takes 1 to 3 years.

3. Clinical Research: The Trial Phases

Clinical trials are the cornerstone of the drug development process. They test safety and efficacy in human subjects through a structured, phased approach, each phase designed to answer increasingly specific questions about the drug’s behaviour and benefit.

Clinical development is divided into four phases:

Phase I: First-in-Human Safety Testing

Participants: 20–100 healthy volunteers or patients

Duration: Several months to 1 year

Primary focus: Safety, dosing, and pharmacokinetics

Phase I trials mark the first time a drug candidate is administered to humans. The primary objective is not to assess efficacy, but to determine whether the drug is safe at various doses and how the human body processes it.

Researchers monitor participants closely for adverse reactions, establish the maximum tolerated dose, and characterize the drug’s pharmacokinetic profile. Data from Phase I informs the dosing strategy for subsequent trials.

Approximate success rate: ~63% of drugs advance from Phase I to Phase II.

Phase II: Proof of Concept

Participants: Several hundred patients with the target condition

Duration: Several months to 2 years

Primary focus: Efficacy signals and continued safety monitoring

If Phase I results are acceptable, the drug enters Phase II — the first real test against the disease it’s intended to treat. These trials enroll patients who have the condition, allowing researchers to assess whether the drug produces a measurable therapeutic effect.

Phase II also continues to monitor side effects, and researchers begin refining the optimal dose range. This phase is often described as the “proof of concept” stage — the point where a drug demonstrates it can do what it’s supposed to do.

Approximate success rate: Only about 33% of drugs that enter Phase II advance to Phase III.

Phase III: Confirmatory Efficacy and Comparative Studies

Participants: 300–3,000+ patients across multiple sites

Duration: 1 to 4 years

Primary focus: Confirming efficacy, monitoring adverse events, comparative effectiveness

Phase III is the most resource-intensive and critical stage in clinical development. Large, often multinational trials compare the investigational drug against standard-of-care treatments or a placebo to confirm its clinical benefit across a broader patient population.

This phase is designed to generate the statistically robust evidence regulators require for approval. It also surfaces less common adverse events that smaller earlier-stage trials may have missed.

Comparator drugs – approved reference medicines used in the control arm of these trials — play a central role in Phase III study design. Sourcing these comparators reliably and in compliance with regulatory standards is a significant operational challenge for clinical trial sponsors.

Approximate success rate: Only 25–30% of drugs successfully complete Phase III.

After Phase III, the sponsor compiles all clinical and preclinical data into a New Drug Application (NDA) or Biologics License Application (BLA) and submits it to the FDA for review.

Phase IV: Post-Approval Surveillance

Participants: General patient population (real-world use)

Duration: Ongoing

Primary focus: Long-term safety, rare adverse events, effectiveness in broader populations

Phase IV studies begin after a drug receives regulatory approval and enters the market. Also referred to as post-market surveillance, this phase captures data on the drug’s real-world performance across a much larger and more diverse patient population than was enrolled in clinical trials.

Phase IV data can reveal rare side effects that only emerge with widespread use; long-term safety signals; and information about effectiveness in subgroups – elderly patients, paediatric populations, and patients with comorbidities – that may have been underrepresented in earlier trials.

Regulatory agencies may require Phase IV commitments as a condition of approval, and manufacturers are obligated to maintain pharmacovigilance programs throughout a drug’s market life.

Drug Development Timeline: How Long Does Each Phase Take?

One of the most common questions from industry stakeholders and researchers is, “How long does the drug development process actually take?”

The honest answer: longer than most people expect.

Stage	Typical Duration	Notes
Drug Discovery	3–6 years	Target ID through lead selection
Preclinical Research	1–3 years	In vitro and animal studies; IND filing
Phase I Clinical Trials	6 months–1 year	First-in-human safety
Phase II Clinical Trials	1–2 years	Proof of concept
Phase III Clinical Trials	1–4 years	Confirmatory efficacy
FDA Review (NDA/BLA)	6 months–2 years	Priority vs. standard review
Total	10–15+ years	Average across therapeutic areas

These timelines can vary considerably depending on the indication, regulatory pathway, and whether the drug qualifies for expedited review programs such as Breakthrough Therapy Designation, Fast Track, or Priority Review.

4. Regulatory Review

After successfully completing Phase III, the sponsor files an NDA or BLA with the FDA (or equivalent applications with the EMA, PMDA, or other national agencies). This submission represents the complete evidentiary package: every clinical, preclinical, and manufacturing data point collected throughout development.

The FDA review team – comprising medical officers, statisticians, pharmacologists, chemists, and labeling experts — evaluates the totality of the evidence to determine whether the drug’s benefits outweigh its known risks for the proposed indication.

Key outputs of the review process include:

•  Approval or rejection of the NDA/BLA
•  Labeling review to ensure prescribing information accurately reflects the clinical evidence
•  Risk Evaluation and Mitigation Strategies (REMS), where applicable, for drugs with significant safety concerns
•  Manufacturing inspections to verify the facility meets current Good Manufacturing Practice (cGMP) standards

Standard FDA review takes approximately 10–12 months. Drugs that qualify for Priority Review may receive a decision within 6 months.

5. Post-Market Safety Monitoring

Regulatory approval is not the end of the drug development life cycle; it’s the beginning of a new phase of oversight. Post-market safety monitoring is an ongoing requirement that extends throughout the commercial life of the drug.

Manufacturers operate pharmacovigilance programs to collect, analyze, and report adverse event data from healthcare providers, patients, and clinical registries. These programs are designed to detect the following:

• Rare side effects not identified during clinical trials
• Safety signals that emerge from long-term use
• Drug interactions that become apparent only at a population scale
• Outcomes in patient subgroups not well-represented in trials

Regulatory agencies conduct regular facility inspections and manufacturing audits to ensure continued compliance with quality standards. When new safety signals emerge post-approval, agencies may require label updates, prescribing restrictions, or, in serious cases, market withdrawal.

Why Do So Many Drugs Fail During Development?

With only 10–12% of clinical-stage drugs ultimately gaining approval, it’s worth understanding where and why most fail.

Scientific failure is the most common cause: the drug simply doesn’t produce the expected therapeutic effect in humans, even after promising preclinical results. This reflects the well-known challenge of translating animal model findings to human biology.

Safety issues account for a significant proportion of failures, particularly in Phase I and Phase II. Unexpected toxicity — hepatotoxicity, cardiotoxicity, or off-target effects — can halt development at any stage.

Regulatory and clinical trial execution challenges also play a role. Poor trial design, patient recruitment failures, comparator sourcing issues, and supply chain disruptions can delay or derail development programs even when the underlying science is sound.

This is why reliable clinical trial supply, including timely sourcing of comparator drugs, proper labeling, and cold-chain management, is a critical operational backbone for any drug development program.

Clinical Trial Supply Chain Considerations in Drug Development

Clinical trials don’t run on data alone; they run on carefully managed, regulatory-compliant drug supply. Every phase of clinical development requires:

• The investigational medicinal product (IMP) supply – the drug under study, manufactured to GMP standards.
• Comparator drug sourcing – approved reference medicines used in controlled trials, particularly in Phase II and Phase III
• Placebo manufacturing – matched to the active product for blinding purposes
• Ancillary supplies – diluents, devices, and co-medications specified in the protocol

Sourcing comparators is particularly complex in global, multi-site trials. Comparators may be sourced from different markets, require import/export authorization, and must meet the quality and labeling standards of each participating country’s regulatory authority.

Delays in comparator availability are one of the leading causes of clinical trial startup delays, and in competitive therapeutic areas, those delays translate directly into time-to-market risk.

Conclusion

The drug development process is one of the most rigorous scientific and regulatory undertakings in any industry. Each stage from identifying a promising biological target to conducting large-scale confirmatory trials and earning regulatory approval exists for a reason: to ensure that every medicine reaching patients is both safe and genuinely effective.

Understanding how this process works matters not just for researchers and regulators but for everyone involved in supporting it, including the clinical trial supply professionals, logistics partners, and comparator sourcing specialists who keep drug development programs on track.

The science of drug development continues to evolve. Adaptive trial designs, biomarker-driven patient selection, and platform trial models are compressing timelines in some areas. But the fundamental structure—discover, test, validate, and approve—remains the backbone of how new medicines reach the people who need them.

Spring Bio Solution supports pharmaceutical companies and clinical research organizations with comparator drug sourcing, clinical trial supply management, and regulatory-compliant pharmaceutical logistics across all phases of drug development.

Frequently Asked Questions